PCSA vs ATHA vs NUVB vs CRVS vs CASI

For growth investors, Nuvation Bio Inc.

(NUVB) is the stronger pick with 699. 0% revenue growth year-over-year, versus -15. 8% for CASI Pharmaceuticals, Inc. (CASI). Analysts rate Processa Pharmaceuticals, Inc. (PCSA) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Corvus Pharmaceuticals, Inc.

(CRVS) delivered a total return of +401. 4%, compared to -99. 1% for CASI Pharmaceuticals, Inc. (CASI). Over 10 years, the gap is even starker: CRVS returned +17. 1% versus CASI's -99. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), CASI Pharmaceuticals, Inc.

(CASI) is the lower-risk stock at -0. 12β versus Nuvation Bio Inc. 's 2. 04β — meaning NUVB is approximately -1762% more volatile than CASI relative to the S&P 500. On balance sheet safety, Corvus Pharmaceuticals, Inc. (CRVS) carries a lower debt/equity ratio of 2% versus 12% for CASI Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Nuvation Bio Inc.

(NUVB) is pulling ahead at 699. 0% versus -15. 8% for CASI Pharmaceuticals, Inc. (CASI). On earnings-per-share growth, the picture is similar: Processa Pharmaceuticals, Inc. grew EPS 89. 3% year-over-year, compared to -26. 7% for CASI Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Processa Pharmaceuticals, Inc.

(PCSA) is the more profitable company, earning 0. 0% net margin versus -325. 3% for Nuvation Bio Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PCSA leads at 0. 0% versus -338. 7% for NUVB. At the gross margin level — before operating expenses — NUVB leads at 86. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, CASI (31.

1% yield) pays a dividend. PCSA, ATHA, NUVB, CRVS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, CASI Pharmaceuticals, Inc.

(CASI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 12), 31. 1% yield). Nuvation Bio Inc. (NUVB) carries a higher beta of 2. 04 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CASI: -99. 0%, NUVB: -51. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PCSA is a small-cap quality compounder stock; ATHA is a small-cap quality compounder stock; NUVB is a small-cap high-growth stock; CRVS is a small-cap quality compounder stock; CASI is a small-cap income-oriented stock. CASI pays a dividend while PCSA, ATHA, NUVB, CRVS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.